Bristol Pravachol OTC Label Studies, Redefined Population Urged By Cmte.

Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet